Ann: Imugene onCARlytics Doses First Patient in IV Combination, page-99

This is pointless replying.

Posters here are so one eyed and defensive.

I make a comment to say the company has always informed the ASX when they dose the first patient in a given trial.

I get challenged on that point. I then substantiate.

Now I get, Do you expect any announcement for every patient dosed? No I expect an announcement for the first patient of a trial.

15th of April open date, that's 70 days without no one being enrolled. Given they presented the trial and their complete response at the annual Bile duct cancer conference earlier this year. Spin it how you will. But I find it really odd that they suddenly enrolled a Bile duct patient into a different study. With continued lack of progress and no announcements from MAST.